Holen Sie sich die Stockscreener-App
11.68
3.36%
0.38
Handel nachbörslich:
11.68
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Chardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth - Yahoo Finance
Charles Schwab Investment Management Inc. Boosts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) pulls back 9.1% this week, but still delivers shareholders solid 136% return over 1 year - Simply Wall St
Fmr LLC Lowers Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics’ (STOK) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average Target Price from Analysts - MarketBeat
Stoke therapeutics' general counsel sells $185,978 in stock - Investing.com
Stoke Therapeutics chief medical officer sells $33,595 in stock By Investing.com - Investing.com UK
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Stoke Therapeutics chief medical officer sells $33,595 in stock - Investing.com
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock By Investing.com - Investing.com Canada
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock - Investing.com India
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock By Investing.com - Investing.com UK
(STOK) Investment Report - Stock Traders Daily
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Intech Investment Management LLC Invests $160,000 in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study - GuruFocus.com
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - newsbreak.com
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug - MSN
Stoke Therapeutics' Dravet Drug Shows Remarkable 87% Seizure Reduction in Clinical Data - StockTitan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lifted by RTW Investments LP - MarketBeat
U.S. STOCKS Stoke Therapeutics, Foot Locker, Marvell - XM
Pure Storage Posts Upbeat Results, Joins Cross Country… - Inkl
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Nigeria
Stoke Therapeutics Shares Rise Premarket on Key FDA Designation - MarketWatch
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap By Investing.com - Investing.com South Africa
Stoke Therapeutics CMO sells $120,698 in stock By Investing.com - Investing.com Canada
Stoke Therapeutics CMO sells $120,698 in stock - Investing.com India
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Business Wire
Stoke Therapeutics: First Disease Modifying Therapy For Dravet, Still In Need Of Regulatory Clarity (NASDAQ:STOK) - Seeking Alpha
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - PharmaVoice
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World
How To Trade (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 8.3%What's Next? - MarketBeat
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):